Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 1.00 (5.714%)
Open: 18.00
High: 18.00
Low: 18.00
Prev. Close: 18.00
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of Slimbiome in Nutri-bites

8 Mar 2018 07:00

RNS Number : 9874G
OptiBiotix Health PLC
08 March 2018
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 Launch of Slimbiome® in Nutri-bites®

 

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, announces the launch of its award winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients ("CII"), at the 2018 Natural Products Expo West & Engredea. The exhibition is the world's largest trade show for organic, natural and healthy products and typically attract more than 80,000 food and ingredient buyers from around the world. OptiBiotix will join CII at stand 3788.

 

OptiBiotix has partnered with specialty ingredients manufacturer CII Ingredients, to launch its patented weight management technology, SlimBiome® in CII's Nutri-Bites® range of cereal based food products. This extends SlimBiome® applications from snack bars and shakes to breakfast cereals and bakery products (e.g. cookies, cakes and tortillas) as well as increasing the range of options for healthy snacks, yoghurts and cereal bars.

 

Products in the Nutri-Bites® range contain expanded cereal pieces and are formulated with a choice of protein sizes and content. These can be applied to granola and snack mix inclusions, nutritional and cereal bars and coated snacks, or just used as a healthy crunch topping.

 

This is a continuation of OptiBiotix's focus on the US market following last years supply & manufacturing Aareement with CII, announced on 12 December 2017. SlimBiome® is the first in a range of products which helps to improve human health through the science of the microbiome. Other products under development in the range include ImmunoBiome, ® CardioBiome® and WellBiome®.

 

Cereal Ingredients is a privately held speciality ingredients manufacturer based in Kansas, USA, dedicated to the development, manufacture and supply of unique, high-quality food ingredients which contribute a meaningful point of difference.

 

Christina Wood, OptiBiotix Sales and Marketing Director, said: "Many cereals and snack bars on the market are deceptively high in sugar and calories, leading consumers with healthy intentions who use these products to gain, rather than lose, weight. By combining OptiBiotix's award winning SlimBiome® technology with CII's market-leading ingredients manufacturing capacity and product development, we have created a delicious functional solution which can help customers manage their weight by reducing snacking and food intake without food cravings. We are delighted to share this innovative science based approach to weight management with food and ingredient buyers from around the world at the Natural Products Expo West & Engredea show."

 

For more information about Optibiotix, please visit www.optibiotix.com

 

 

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUBSARWSAORAR
Date   Source Headline
19th Mar 20204:38 pmRNSPrice Monitoring Extension
19th Mar 20202:06 pmRNSSecond Price Monitoring Extn
19th Mar 20202:01 pmRNSPrice Monitoring Extension
19th Mar 202011:05 amRNSSecond Price Monitoring Extn
19th Mar 202011:00 amRNSPrice Monitoring Extension
17th Mar 20207:00 amRNSDistribution Agreement for SlimBiome® Medical
16th Mar 202011:56 amRNSDirector’s Dealing
12th Mar 20204:44 pmRNSSecond Price Monitoring Extn
12th Mar 20204:39 pmRNSPrice Monitoring Extension
12th Mar 20202:05 pmRNSSecond Price Monitoring Extn
12th Mar 20202:00 pmRNSPrice Monitoring Extension
12th Mar 20207:00 amRNSNew partner for LPLDL® in Bulgaria
11th Mar 20207:00 amRNSExtension of LPLDL® supply agreement with SACCO
25th Feb 20207:00 amRNSMarketing update
17th Feb 20207:06 amRNSDistributor agreement for LPLDL®
12th Feb 20207:00 amRNSExtension of LPLDL® into Dairy Products
31st Jan 20207:00 amRNSLaunch of SlimBiome® in North America
28th Jan 20207:00 amRNSExtension of term and territories for products
27th Jan 20207:00 amRNSLaunch of LPLDL® product with AlfaSigma
17th Jan 20207:00 amRNSTrading Update
8th Jan 20207:00 amRNSLPLDL® reduces high blood pressure
7th Jan 20207:00 amRNSLaunch of SlimBiome® range in Holland & Barrett
19th Dec 20197:00 amRNSSlimBiome® distribution agreement for Germany
17th Dec 20197:00 amRNSAnthem BioPharma launches two products in India
9th Dec 20197:00 amRNSDistribution agreement for CholBiome®x3
6th Dec 20197:00 amRNSGoFigure® and SlimBiome® commercial updates
5th Dec 20197:00 amRNSSlimBiome® Medical update
4th Dec 20197:00 amRNSAppointment of European Sales Leader - ProBiotix
6th Nov 201910:38 amRNSHolding(s) in Company
9th Oct 20197:00 amRNSLPLDL® Pharmaceutical GMP process validation
18th Sep 20197:00 amRNSGoFigure® agreement for Southern Africa
28th Aug 201910:00 amRNSDirector's Dealing
28th Aug 20197:00 amRNSDirectorate Change
28th Aug 20197:00 amRNSHolding(s) in Company
28th Aug 20197:00 amRNSHalf-year Report
12th Aug 20197:00 amRNSManufacturing, supply and profit sharing agreement
29th Jul 20194:03 pmRNSTransfer of certain SkinBioTherapeutics plc shares
18th Jul 20197:00 amRNSOnline distribution agreement - SlimBiome® Medical
11th Jul 20197:00 amRNSScientific and commercial update
3rd Jul 20197:00 amRNSLicense agreement for LPLDL® in Japan
1st Jul 20197:00 amRNSLPLDL® license agreement with Kappa Bioscience AS
25th Jun 20197:00 amRNSAppointment of goetzpartners securities Limited
24th Jun 20197:00 amRNSManufacturing agreement with Agropur
11th Jun 20194:55 pmRNSResult of AGM
10th Jun 20197:00 amRNSLicense agreement for CholBiome® in Vietnam
29th May 20193:17 pmRNSDirector's Dealing
28th May 20197:00 amRNSAppointment of CEO of ProBiotix Health
22nd May 20197:00 amRNSGoFigure® distribution agreement for Poland
20th May 20197:00 amRNSLicense agreement for LPLDL®
17th May 20197:00 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.